StockNews.com initiated coverage on shares of IRIDEX (NASDAQ:IRIX – Get Free Report) in a report released on Sunday. The firm set a “hold” rating on the medical equipment provider’s stock.
IRIDEX Price Performance
IRIX stock opened at $1.63 on Friday. The business has a 50 day simple moving average of $1.70 and a 200-day simple moving average of $1.81. The firm has a market capitalization of $27.17 million, a PE ratio of -2.44 and a beta of 0.82. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.54 and a quick ratio of 0.85. IRIDEX has a 1 year low of $1.27 and a 1 year high of $3.65.
IRIDEX (NASDAQ:IRIX – Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The medical equipment provider reported ($0.12) earnings per share for the quarter. IRIDEX had a negative net margin of 22.79% and a negative return on equity of 192.95%. The firm had revenue of $11.58 million for the quarter. During the same quarter last year, the firm posted ($0.11) earnings per share.
IRIDEX Company Profile
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.
Read More
- Five stocks we like better than IRIDEX
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- 2 Stocks to Gain From Trump Universal Tariffs on Critical Imports
- The How and Why of Investing in Gold Stocks
- Rigetti Computing, Inc.: Buy, Sell, or Hold for 2025
- Where to Find Earnings Call Transcripts
- Delta Can Fly to New Highs in 2025; Here’s Why
Receive News & Ratings for IRIDEX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IRIDEX and related companies with MarketBeat.com's FREE daily email newsletter.